Key Developments For ATS Medical, Inc.
ATS Medical, Inc. (ATSI.O) (Consolidated Issue listed on NASDAQ Global Market)
ATS Medical, Inc. Reaffirms FY 2009 Revenue Guidance; Comments On Q4 2009 Net Income Guidance
ATS Medical, Inc. reaffirmed fiscal 2009 guidance and expects revenue guidance of $77-$79 million. Additionally, the Company anticipates it may generate net income in the fourth quarter of 2009. According to Reuters Estimates, analysts were expecting the Company to report revenues of $78 million for fiscal 2009; net profit of $0.64 for fourth quarter of 2009.
ATS Medical, Inc. Announces Receipt Of CE Mark For The New ATS CryoMaze 10-S Probe
ATS Medical, Inc. announced the receipt of CE Mark for the ATS CryoMaze 10-S Surgical Cryoablation Probe for the treatment of cardiac arrhythmias.
ATS Medical, Inc. Announces FDA Approval for Clinical Investigation of ATS 3f Aortic Bioprosthesis
ATS Medical, Inc. announced that the FDA has approved a clinical study in which cardiac surgeons will implant the ATS 3f Aortic Bioprosthesis in a younger aortic valve replacement patient population that has not been previously studied in a controlled and scientific manner. This new FDA approved clinical study will enroll patients younger than 60 years of age, with half of the population younger than 50 years of age. The Company believes that this study will ultimately demonstrate the safety, efficacy and durability of the ATS 3f Aortic Bioprosthesis in this new patient population, while illustrating the performance necessary to maintain the active lifestyle of the younger population. The ATS 3f Aortic Bioprosthesis is an aortic valve designed to function just like a native valve. Its tubular design was inspired by how a native valve forms in utero: as a tube with sides that collapse when external pressure is applied. The primary benefit of the ATS 3f Aortic Bioprosthesis is its tubular design and that it restores physiologic non turbulent blood flow and native-like stress distribution to the aortic root. This valve design provides surgeons and patients with a potentially more durable solution to aortic valve replacement.
ATS Medical, Inc. Reaffirms FY 2009 Revenue Guidance; Reaffirms Q4 2009 Profit Guidance-Conference Call
ATS Medical, Inc. reaffirmed fiscal 2009 guidance for revenue to be in the range of $77 to $79 million. The Company expects to generate net profit in the fourth quarter of 2009. According to Reuters Estimates, analysts on an average are expecting the Company to report revenue of $78 million for fiscal 2009; net profit of $0.64 million for the fourth quarter of 2009.
ATS Medical, Inc. Lowers High End Of Prior FY 2009 Revenue Guidance Range; Reaffirms Q4 2009 Earnings Guidance
ATS Medical, Inc. announced that for fiscal 2009 the Company revised its previous revenue guidance of $77-$80 million to $77-$79 million. The adjustment to revenue guidance is primarily related to the termination of the Company's distribution contract for an anastomotic assist product the Company has distributed since October 2006. Additionally, the Company continues to expect to generate an operating profit on an annual basis and net income in the fourth quarter of 2009. According to Reuters Estimates, analysts were expecting the Company to report revenues of $79 million for fiscal 2009; EBIT of $1.93 million for fourth quarter of 2009.
